Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 7, 2013 - Issue
Submit an article Journal homepage
98
Views
12
CrossRef citations to date
0
Altmetric
Original Research

In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features

Mingli Xiang1 The State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, People’s Republic of ChinaCorrespondence[email protected]
,
Kai Lei1 The State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, People’s Republic of China
,
Wenjie Fan1 The State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, People’s Republic of China
,
Yuchun Lin2 Department of Chemical and Biomolecular Engineering, University of California, Berkeley, CA, USA
,
Gu He1 The State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, People’s Republic of China
,
Mingli Yang3 Institute of Atomic and Molecular Physics, Sichuan University, Chengdu, People’s Republic of China
,
Lijuan Chen1 The State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, People’s Republic of China
&
Yirong Mo4 Department of Chemistry, Western Michigan University, Kalamazoo, MI, USA
 show all
Pages 789-839 | Published online: 14 Aug 2013

References

  • Shimizu N Behzadian MA Shimizu Y Genetics of cell surface receptors for bioactive polypeptides: binding of epidermal growth factor is associated with the presence of human chromosome 7 in human-mouse cell hybrids Proc Natl Acad Sci U S A 1980 77 6 3600 3604 6968072
  • Schlessinger J Cell signaling by receptor tyrosine kinases Cell 2000 103 2 211 225 11057895
  • Yarden Y Sliwkowski MX Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2001 2 2 127 137 11252954
  • Zhou W Ercan D Chen L Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 2009 462 7276 1070 1074 20033049
  • Carmi C Cavazzoni A Vezzosi S Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion J Med Chem 2010 53 5 2038 2050 20151670
  • Bai F Liu H Tong L Discovery of novel selective inhibitors for EGFR-T790M/L858R Bioorg Med Chem Lett 2012 22 3 1365 1370 22227214
  • Li S Guo C Sun X Synthesis and biological evaluation of quinazoline and quinoline bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors and EPR bio-probe agents Eur J Med Chem 2012 49 271 278 22309911
  • Sato T Watanabe H Tsuganezawa K Identification of novel drug-resistant EGFR mutant inhibitors by in silico screening using comprehensive assessments of protein structures Bioorg Med Chem 2012 20 12 3756 3767 22607878
  • Salomon DS Brandt R Ciardiello F Normanno N Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 1995 19 3 183 232 7612182
  • Roskoski R The ErbB/HER receptor protein-tyrosine kinases and cancer Biochem Biophys Res Commun 2004 319 1 1 11 15158434
  • Gazdar AF Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors Oncogene 2009 28 Suppl 1 S24 S31 19680293
  • Lemmon MA Schlessinger J Cell signaling by receptor tyrosine kinases Cell 2010 141 7 1117 1134 20602996
  • Lurje G Lenz HJ EGFR signaling and drug discovery Oncology 2009 77 6 400 410 20130423
  • Hynes NE Lane HA ERBB receptors and cancer: the complexity of targeted inhibitors Nat Rev Cancer 2005 5 5 341 354 15864276
  • Doebele RC Oton AB Peled N Camidge DR Bunn PA New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer Lung Cancer 2010 69 1 1 12 20092908
  • Sequist LV Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer Oncologist 2007 12 3 325 330 17405897
  • Yun CH Mengwasser KE Toms AV The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc Natl Acad Sci U S A 2008 105 6 2070 2075 18227510
  • Schneider MR Wolf E The epidermal growth factor receptor ligands at a glance J Cell Physiol 2009 218 3 460 466 19006176
  • Lupberger J Zeisel MB Xiao F EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy Nat Med 2011 17 5 589 595 21516087
  • Spicer JF Rudman SM EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992 Target Oncol 2010 5 4 245 255 20574858
  • Rocha-Lima CM Soares HP Raez LE Singal R EGFR targeting of solid tumors Cancer Control 2007 14 3 295 304 17615536
  • Okamoto I Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy FEBS J 2010 277 2 309 315 19922468
  • Ciardiello F Tortora G EGFR antagonists in cancer treatment New Engl J Med 2008 358 11 1160 1174 18337605
  • Kobayashi S Ji H Yuza Y An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor Cancer Res 2005 65 16 7096 7101 16103058
  • Greulich H Chen TH Feng W Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants PLoS Med 2005 2 11 e313 16187797
  • Riely GJ Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer J Thorac Oncol 2008 3 6 Suppl 2 S146 S149 18520300
  • Liu B Bernard B Wu JH Impact of EGFR point mutations on the sensitivity to gefitinib: insights from comparative structural analyses and molecular dynamics simulations Proteins 2006 65 2 331 346 16927343
  • Wissner A Mansour TS The development of HKI-272 and related compounds for the treatment of cancer Arch Pharm (Weinheim) 2008 341 8 465 477 18493974
  • Li D Ambrogio L Shimamura T BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 2008 27 34 4702 4711 18408761
  • Engelman JA Zejnullahu K Gale CM PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib Cancer Res 2007 67 24 11924 11932 18089823
  • Kwak EL Sordella R Bell DW Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib Proc Natl Acad Sci U S A 2005 102 21 7665 7670 15897464
  • Godin-Heymann N Ulkus L Brannigan BW The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor Mol Cancer Ther 2008 7 4 874 879 18413800
  • Blair JA Rauh D Kung C Structure-guided development of affinity probes for tyrosine kinases using chemical genetics Nat Chem Biol 2007 3 4 229 238 17334377
  • Tsou HR Overbeek-Klumpers EG Hallett WA Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity J Med Chem 2005 48 4 1107 1131 15715478
  • Wissner A Overbeek E Reich MF Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2) J Med Chem 2003 46 1 49 63 12502359
  • Wissner A Brawner Floyd MB Rabindran SK Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents Bioorg Med Chem Lett 2002 12 20 2893 2897 12270171
  • Tsou HR Mamuya N Johnson BD 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced ant-itumor activity J Med Chem 2001 44 17 2719 2734 11495584
  • Marvin http://www.chemaxon.com [computer program] Version 5.6.0.1 ChemAxon Ltd 2011
  • Halgren TA Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 J Comput Chem 1996 17 5–6 490 519
  • Gaussian 03 [computer program] Version Revision C.02 Wallingford CT Gaussian, Inc 2004
  • Yang W Mortier WJ The use of global and local molecular parameters for the analysis of the gas-phase basicity of amines J Am Chem Soc 1986 108 19 5708 5711 22175316
  • Boström J Reproducing the conformations of protein-bound ligands: a critical evaluation of several popular conformational searching tools J Comput Aided Mol Des 2001 15 12 1137 1152 12160095
  • Discovery Studio Modeling Environment [computer program] Version Release 3.1 San Diego Accelrys Software Inc 2012
  • Michalczyk A Klüter S Rode HB Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR Bioorg Med Chem 2008 16 7 3482 3488 18316192
  • FRED program http://www.eyesopen.com [computer program] Version Version 2.2.5 OpenEye Scientific Software Inc Santa Fe, NM, USA 2012
  • Nicholls A Grant JA Brown FK Gaussian docking functions Biopolymers 2003 68 1 76 90 12579581
  • Verkhivker GM Bouzida D Gehlhaar DK Deciphering common failures in molecular docking of ligand-protein complexes J Comput Aided Mol Des 2000 14 8 731 751 11131967
  • Eldridge MD Murray CW Auton TR Paolini GV Mee RP Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes J Comput Aided Mol Des 1997 11 5 425 445 9385547
  • Stahl M Rarey M Detailed analysis of scoring functions for virtual screening J Med Chem 2001 44 7 1035 1042 11297450
  • Grant JA Pickup BT Nicholls A A smooth permittivity function for Poisson-Boltzmann solvation methods J Comput Chem 2001 22 6 608 640
  • Traxler P Furet P Strategies toward the design of novel and selective protein tyrosine kinase inhibitors Pharmacol Ther 1999 82 2–3 195 206 10454197
  • Cavasotto CN Ortiz MA Abagyan RA Piedrafita FJ In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells Bioorg Med Chem Lett 2006 16 7 1969 1974 16413185
  • Rode HB Sos ML Grütter C Heynck S Simard JR Rauh D Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino) isoquinoline-4-carbonitriles as inhibitors of myosin light chain kinase and epidermal growth factor receptor Bioorg Med Chem 2011 19 1 429 439 21130659
  • Dror O Shulman-Peleg A Nussinov R Wolfson HJ Predicting molecular interactions in silico: I. A guide to pharmacophore identification and its applications to drug design Curr Med Chem 2004 11 1 71 90 14754427
  • Güner OF History and evolution of the pharmacophore concept in computer-aided drug design Curr Top Med Chem 2002 2 12 1321 1332 12470283
  • Xiang M Cao Y Fan W Chen L Mo Y Computer-aided drug design: lead discovery and optimization Comb Chem High Throughput Screen 2012 15 4 328 337 22221065
  • Davis AM Teague SJ Kleywegt GJ Application and limitations of X-ray crystallographic data in structure-based ligand and drug design Angew Chem Int Ed Engl 2003 42 24 2718 2736 12820253
  • Tuccinardi T Docking-based virtual screening: recent developments Comb Chem High Throughput Screen 2009 12 3 303 314 19275536
  • Plewczynski D Łazniewski M von Grotthuss M Rychlewski L Ginalski K VoteDock: consensus docking method for prediction of protein-ligand interactions J Comput Chem 2011 32 4 568 581 20812324
  • Schapira M Abagyan R Totrov M Nuclear hormone receptor targeted virtual screening J Med Chem 2003 46 14 3045 3059 12825943
  • Ravindranathan KP Mandiyan V Ekkati AR Bae JH Schlessinger J Jorgensen WL Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening J Med Chem 2010 53 4 1662 1672 20121196

References

  • Wissner A Brawner Floyd MB Rabindran Sridhar K Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents Bioorg Med Chem Lett 2002 12 20 2893 2897 12270171
  • Wissner A Overbeek E Reich MF Synthesis and Structure-Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2) J Med Chem 2003 46 1 49 63 12502359
  • Tsou H-R Overbeek-Klumpers EG Hallett WA Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity J Med Chem 2005 48 4 1107 1131 15715478
  • Tsou H-R Mamuya N Johnson BD 6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity J Med Chem 2001 44 17 2719 2734 11495584

References

  • Wissner A Brawner Floyd MB Rabindran Sridhar K Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents Bioorg Med Chem Lett 2002 12 20 2893 2897 12270171
  • Wissner A Overbeek E Reich MF Synthesis and Structure-Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2) J Med Chem 2003 46 1 49 63 12502359
  • Tsou H-R Overbeek-Klumpers EG Hallett WA Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity J Med Chem 2005 48 4 1107 1131 15715478
  • Tsou H-R Mamuya N Johnson BD 6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity J Med Chem 2001 44 17 2719 2734 11495584
  • Zhou W Ercan D Chen L Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 2009 462 7276 1070 1074 20033049

References

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.